Targeted agents plus CHOP compared with CHOP as the first-line treatment for newly diagnosed patients with peripheral T-cell lymphoma (GUIDANCE-03): an open-label, multicentre phase 2 clinical trialResearch in context

• Main Authors: Ming-Ci Cai (Author), Shu Cheng (Author), Hong-Mei Jing (Author), Yan Liu (Author), Guo-Hui Cui (Author), Ting Niu (Author), Jian-Zhen Shen (Author), Liang Huang (Author), Xin Wang (Author), Yao-Hui Huang (Author), Li Wang (Author), Peng-Peng Xu (Author), Wei-Li Zhao (Author)
• Format: Book
• Published: Elsevier, 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: Peripheral T-cell lymphoma (PTCL) is a heterogeneous disease with dismal outcomes. We conducted an open-label, phase 2 nonrandomised, externally controlled study to evaluate the efficacy and safety of targeted agents plus CHOP (cyclophosphamide, doxorubicin, vincristine, and pre...